Cocco G, Strozzi C, Chu D
Clin Cardiol. 1979 Jun;2(3):212-6. doi: 10.1002/clc.4960020307.
The electrophysiological effect of dimeditiapramine (Ro 11-1781), a Ca2+ antagonist, was evaluated in 20 patients with coronary heart disease. Electrophysiological measurements, including sinus cycle length, sinoatrial conduction time, intra-atrial conduction time, atrial, atrioventricular, nodal and ventricular refractory periods and intraventricular conduction time were recorded before and after the intravenous administration of Ro 11-1781. At a dose which is effective against cardiac arrhythmias, Ro 11-1781 produced no statistical significant changes in the sinoatrial and intraventricular conduction time. Similarly, neither the sinoatrial nor the ventricular refractory period was affected. Ro 11-1781, however, increased the atrioventricular conduction time and decreased the systolic blood pressure to a statistically significant extent. The tolerance was very good.
对20例冠心病患者评估了钙拮抗剂二甲替嗪（Ro 11 - 1781）的电生理效应。在静脉注射Ro 11 - 1781之前和之后，记录了包括窦性周期长度、窦房传导时间、心房内传导时间、心房、房室、结区和心室不应期以及室内传导时间在内的电生理指标。在对心律失常有效的剂量下，Ro 11 - 1781对窦房和室内传导时间没有产生统计学上的显著变化。同样，窦房和心室不应期均未受影响。然而，Ro 11 - 1781显著延长了房室传导时间并降低了收缩压。耐受性非常好。
